Eli Lilly & Co ( (LLY) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Eli Lilly’s stock took a notable dive due to the company’s downward revision of its fourth-quarter revenue forecasts for its weight-loss drug, Zepbound, and diabetes treatment, Mounjaro. This change was driven by an expected quick expansion in the U.S. incretin market and lower-than-anticipated year-end channel inventory. Despite this setback, Eli Lilly maintains a positive long-term outlook, forecasting strong revenue growth by 2025, thanks to its diverse pharmaceutical portfolio and innovative therapies. The company is investing in production facilities to meet the rising demand for GLP-1 drugs and is progressing with its experimental weight-loss pill, orforglipron, which could receive regulatory approval by 2026. These strategic moves are aimed at capturing the growing market and securing future growth.
More about Eli Lilly & Co
YTD Price Performance: 2.49%
Average Trading Volume: 3,891,669
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $759.4B
For further insights into LLY stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.